Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/74551
Title: Evaluation of CD44s, CD44v6, CXCR2, CXCL1, and IL-1β in Benign and Malignant Tumors of Salivary Glands
Authors: Fonthip Laohavisudhi
Titikorn Chunchai
Natnicha Ketchaikosol
Wacharaporn Thosaporn
Nipon Chattipakorn
Siriporn C. Chattipakorn
Authors: Fonthip Laohavisudhi
Titikorn Chunchai
Natnicha Ketchaikosol
Wacharaporn Thosaporn
Nipon Chattipakorn
Siriporn C. Chattipakorn
Keywords: Biochemistry, Genetics and Molecular Biology
Issue Date: 1-May-2022
Abstract: Background: Several studies have reported an association between high expression of CD44 in different types of cancer. However, no study has reported a link among CD44 expression, other biomarkers, and the aggressiveness of salivary gland tumors. Methods: A total of 38 specimens were obtained from non-tumorous salivary glands, benign and malignant tumors in salivary glands. Immunohistochemical analyses of CD44s, CD44v6, IL-1β, CXCL1, and CXCR2 were performed, and the area of positive cells was assessed. Results: We found that both CD44s and CXCR2 expression were increased in the benign and malignant groups. CD44v6 was also increased in both groups, but it had the highest level in the malignant group. IL-1β was the only biomarker that increased significantly in the malignant group in comparison to the other two groups. Conclusions: CD44s, CD44v6, CXCR2, and IL-1β expressions were found to be higher in salivary gland tumors. However, IL-1β alone may play a crucial role in the aggressiveness of salivary gland tumors as this cytokine was expressed only in the malignant group with high expression associated with high-grade malignancy.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85130867665&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/74551
ISSN: 20754418
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.